Protease Inhibitors

"Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).

Descriptor ID	D011480
MeSH Number(s)	D27.505.519.389.745
Concept/Terms	Protease Inhibitors Protease Inhibitors Inhibitors, Protease Endopeptidase Inhibitors Inhibitors, Endopeptidase Protease Inhibitor Inhibitor, Protease Peptide Hydrolase Inhibitors Hydrolase Inhibitors, Peptide Inhibitors, Peptide Hydrolase Peptide Peptidohydrolase Inhibitors Inhibitors, Peptide Peptidohydrolase Peptidohydrolase Inhibitors, Peptide Protease Antagonists Antagonists, Protease Antiproteases Peptidase Inhibitors Inhibitors, Peptidase

Below are MeSH descriptors whose meaning is more general than "Protease Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protease Inhibitors [D27.505.519.389.745]

Below are MeSH descriptors whose meaning is related to "Protease Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Protease Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Protease Inhibitors" by people in this website by year, and whether "Protease Inhibitors" was a major or minor topic of these publications.

Bar chart showing 55 publications over 24 distinct years, with a maximum of 6 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1997	1	0	1
2001	1	2	3
2002	1	0	1
2003	1	1	2
2004	1	2	3
2005	1	0	1
2008	1	5	6
2009	3	0	3
2010	2	1	3
2011	0	3	3
2012	1	0	1
2013	3	0	3
2014	1	1	2
2015	1	0	1
2016	2	1	3
2017	1	1	2
2018	1	0	1
2019	3	0	3
2020	1	0	1
2021	3	2	5
2022	0	4	4
2023	0	1	1
2024	0	1	1

Below are the most recent publications written about "Protease Inhibitors" by people in Profiles.

Cruz KG, Alexander K, Makhaik S, Hardy JA. FRET Probes for Detection of Both Active and Inactive Zika Virus Protease. Biochemistry. 2024 Dec 17; 63(24):3300-3309.

View in: PubMed
Zvornicanin SN, Shaqra AM, Huang QJ, Ornelas E, Moghe M, Knapp M, Moquin S, Dovala D, Schiffer CA, Kurt Yilmaz N. Crystal Structures of Inhibitor-Bound Main Protease from Delta- and Gamma-Coronaviruses. Viruses. 2023 03 18; 15(3).

View in: PubMed
Zephyr J, Rao DN, Johnson C, Shaqra AM, Nalivaika EA, Jordan A, Kurt Yilmaz N, Ali A, Schiffer CA. Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease. Bioorg Chem. 2023 02; 131:106269.

View in: PubMed
Mondal S, Chen Y, Lockbaum GJ, Sen S, Chaudhuri S, Reyes AC, Lee JM, Kaur AN, Sultana N, Cameron MD, Shaffer SA, Schiffer CA, Fitzgerald KA, Thompson PR. Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2. J Am Chem Soc. 2022 11 23; 144(46):21035-21045.

View in: PubMed
Shaqra AM, Zvornicanin SN, Huang QYJ, Lockbaum GJ, Knapp M, Tandeske L, Bakan DT, Flynn J, Bolon DNA, Moquin S, Dovala D, Kurt Yilmaz N, Schiffer CA. Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat Commun. 2022 06 21; 13(1):3556.

View in: PubMed
Flynn JM, Samant N, Schneider-Nachum G, Barkan DT, Yilmaz NK, Schiffer CA, Moquin SA, Dovala D, Bolon DNA. Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms. Elife. 2022 06 20; 11.

View in: PubMed
Zephyr J, Kurt Yilmaz N, Schiffer CA. Viral proteases: Structure, mechanism and inhibition. Enzymes. 2021; 50:301-333.

View in: PubMed
Nageswara Rao D, Zephyr J, Henes M, Chan ET, Matthew AN, Hedger AK, Conway HL, Saeed M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. J Med Chem. 2021 08 26; 64(16):11972-11989.

View in: PubMed
Hall MD, Anderson JM, Anderson A, Baker D, Bradner J, Brimacombe KR, Campbell EA, Corbett KS, Carter K, Cherry S, Chiang L, Cihlar T, de Wit E, Denison M, Disney M, Fletcher CV, Ford-Scheimer SL, G?tte M, Grossman AC, Hayden FG, Hazuda DJ, Lanteri CA, Marston H, Mesecar AD, Moore S, Nwankwo JO, O'Rear J, Painter G, Singh Saikatendu K, Schiffer CA, Sheahan TP, Shi PY, Smyth HD, Sofia MJ, Weetall M, Weller SK, Whitley R, Fauci AS, Austin CP, Collins FS, Conley AJ, Davis MI. Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit. J Infect Dis. 2021 Jul 15; 224(Supplement_1):S1-S21.

View in: PubMed
Lockbaum GJ, Henes M, Talledge N, Rusere LN, Kosovrasti K, Nalivaika EA, Somasundaran M, Ali A, Mansky LM, Kurt Yilmaz N, Schiffer CA. Inhibiting HTLV-1 Protease: A Viable Antiviral Target. ACS Chem Biol. 2021 03 19; 16(3):529-538.

View in: PubMed

People

Explore

Similar Concepts

Top Journals